EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Related Terms
Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
ROCO:7427 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a EBITDA Margin % of -8,455.84% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #873 out of 942 companies in the Biotechnology industry, placing it in the top 92.7%.
Is Great Novel Therapeutics Biotech & Medicals' EBITDA Margin % too high?
Great Novel Therapeutics Biotech & Medicals' current EBITDA Margin % is -8,455.84%. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #873 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #873 out of 942 companies for EBITDA Margin %. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current EBITDA Margin % is -8,455.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.57, compared to a current price of NT$40.15 — trading 57% above its estimated fair value. The current EBITDA Margin % is -8,455.84%. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current EBITDA Margin % is -8,455.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$40.15 is trading 57% above its estimated GF Value™ of NT$25.57.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
EBITDA Margin %: -8,455.84%
GF Value™: NT$25.57 vs. price of NT$40.15 (57% above fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
52GF Score
Get the complete analysis for ROCO:7427
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
